SI2185686T1 - Dendritične celice - Google Patents
Dendritične celiceInfo
- Publication number
- SI2185686T1 SI2185686T1 SI200830573T SI200830573T SI2185686T1 SI 2185686 T1 SI2185686 T1 SI 2185686T1 SI 200830573 T SI200830573 T SI 200830573T SI 200830573 T SI200830573 T SI 200830573T SI 2185686 T1 SI2185686 T1 SI 2185686T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dendritic cells
- fragment
- associated antigen
- tumor associated
- nucleic acid
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4238—Regulators of development
- A61K40/424—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4275—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07450139A EP2025746A1 (en) | 2007-08-16 | 2007-08-16 | Dendritic cells |
| EP08787211A EP2185686B1 (en) | 2007-08-16 | 2008-08-14 | Dendritic cells |
| PCT/EP2008/060668 WO2009021982A1 (en) | 2007-08-16 | 2008-08-14 | Dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2185686T1 true SI2185686T1 (sl) | 2012-04-30 |
Family
ID=38683479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200830573T SI2185686T1 (sl) | 2007-08-16 | 2008-08-14 | Dendritične celice |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110097346A1 (sl) |
| EP (3) | EP2025746A1 (sl) |
| JP (2) | JP5475661B2 (sl) |
| AT (1) | ATE543900T1 (sl) |
| DK (1) | DK2185686T3 (sl) |
| ES (1) | ES2381612T3 (sl) |
| PL (1) | PL2185686T3 (sl) |
| SI (1) | SI2185686T1 (sl) |
| WO (1) | WO2009021982A1 (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2767595A1 (en) * | 2009-07-09 | 2011-01-13 | South Alabama Medical Science | Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| KR102121492B1 (ko) | 2011-05-03 | 2020-06-11 | 이뮤노베이티브 테라피스, 엘티디. | 면역치료를 사용하는 il-12의 유도 |
| KR20140054140A (ko) * | 2011-07-27 | 2014-05-08 | 베일러 리서치 인스티튜트 | 췌장암에 대한 수지상 세포(dc) - 백신 치료요법 |
| CN104830799A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于psa抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス, インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| EP3456343A1 (en) | 2017-08-09 | 2019-03-20 | Dodge Private Equity Ltd. | Vaccine formulation of dendritic cells |
| KR102356510B1 (ko) * | 2017-09-05 | 2022-02-08 | 메디진 이뮤노테라피스 게엠바하 | 수지상 세포 효능 분석 |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| CN112402596B (zh) * | 2019-08-22 | 2023-12-08 | 上海细胞治疗集团有限公司 | 多肽组合物及疫苗 |
| CN112755182A (zh) * | 2019-11-01 | 2021-05-07 | 深圳先进技术研究院 | 一种特异性激活免疫系统的纳米材料的制备和应用 |
| CN116064399B (zh) * | 2022-07-28 | 2025-06-13 | 深圳市新合生物医疗科技有限公司 | 一种检测mRNA特异性免疫激活的方法及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
-
2007
- 2007-08-16 EP EP07450139A patent/EP2025746A1/en not_active Withdrawn
-
2008
- 2008-08-14 DK DK08787211.5T patent/DK2185686T3/da active
- 2008-08-14 AT AT08787211T patent/ATE543900T1/de active
- 2008-08-14 PL PL08787211T patent/PL2185686T3/pl unknown
- 2008-08-14 JP JP2010520579A patent/JP5475661B2/ja not_active Expired - Fee Related
- 2008-08-14 US US12/673,695 patent/US20110097346A1/en not_active Abandoned
- 2008-08-14 EP EP08787211A patent/EP2185686B1/en active Active
- 2008-08-14 EP EP12153095A patent/EP2450052A3/en not_active Withdrawn
- 2008-08-14 ES ES08787211T patent/ES2381612T3/es active Active
- 2008-08-14 WO PCT/EP2008/060668 patent/WO2009021982A1/en not_active Ceased
- 2008-08-14 SI SI200830573T patent/SI2185686T1/sl unknown
-
2014
- 2014-02-05 JP JP2014020434A patent/JP5964872B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-30 US US14/700,890 patent/US20150352199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2450052A3 (en) | 2012-05-30 |
| DK2185686T3 (da) | 2012-05-29 |
| PL2185686T3 (pl) | 2012-07-31 |
| WO2009021982A1 (en) | 2009-02-19 |
| JP2014131510A (ja) | 2014-07-17 |
| ES2381612T3 (es) | 2012-05-29 |
| EP2185686B1 (en) | 2012-02-01 |
| EP2025746A1 (en) | 2009-02-18 |
| ATE543900T1 (de) | 2012-02-15 |
| JP5475661B2 (ja) | 2014-04-16 |
| EP2450052A2 (en) | 2012-05-09 |
| US20110097346A1 (en) | 2011-04-28 |
| JP5964872B2 (ja) | 2016-08-03 |
| JP2010536330A (ja) | 2010-12-02 |
| US20150352199A1 (en) | 2015-12-10 |
| EP2185686A1 (en) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2185686T1 (sl) | Dendritične celice | |
| JP2013510581A5 (sl) | ||
| IL198379A0 (en) | Antibodies binding sphingosine-1-phosphate, nucleic acids encoding the same, and compositions containing the same | |
| IL225849A0 (en) | Molecules with binding ability that can neutralize rabies virus, and their uses | |
| AP2011005592A0 (en) | Microencapsulate and process for the manufacture thereof. | |
| EP2205744A4 (en) | XYLENASES, NUCLEIC ACIDS CODING THEREOF AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| WO2009153775A3 (en) | Methods for distinguishing between specific types of lung cancers | |
| WO2008061213A3 (en) | Genetic variations associated with tumors | |
| PL2293685T3 (pl) | Koncentraty i izolaty białkowe z nasion oleistych i sposoby ich wytwarzania | |
| IL210485A (en) | An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein | |
| NZ776770A (en) | Adam6 mice | |
| MX300732B (es) | Celulasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas. | |
| PL1989302T4 (pl) | Ksylanazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania | |
| IL202327A (en) | An isolated cyclic protein, an isolated nucleic acid encoded for this protein, a host cell containing this nucleic acid sequence and a process for making this cyclic protein | |
| MX338063B (es) | Molecula de union especifica al rsv. | |
| IT1394288B1 (it) | Immunogeni di proteine che legano il fattore h. | |
| WO2010062779A3 (en) | Modified dna polymerases | |
| WO2009029601A3 (en) | Receptor-targeting reagents | |
| WO2009140039A3 (en) | Synthetic antibodies | |
| WO2011147762A3 (en) | Stabilized radiopharmaceutical composition | |
| WO2010134939A3 (en) | Mammalian genes involved in infection | |
| ZA201005032B (en) | Sulfenamide,vulcanization accelerator containing the sulfenamide for rubber,and process for producing the same | |
| IL220359A (en) | Recombinant histolyticum collagenases and a method for their production | |
| WO2008085878A3 (en) | High affinity antibodies that neutralize staphylcoccus enterotoxin b | |
| PL1863747T3 (pl) | Sposób hydroformylowania o ulepszonej izo-selektywności |